Specifically, CYP2W1 was detected in 51.6% of high-grade tumors and 71.4% of Stage IV cases, suggesting a potential role for CYP2W1 in promoting tumor aggressiveness and progression in pediatric STSs. This evidence concerns the gene CYP2W1 and neoplasm.